Trinity Biotech PLC

TRIB Healthcare Medical Devices

Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024. In the quarter to March 2026, revenue grew 43.3%, EPS grew 52.1%, free cash flow grew 75.2% and total debt rose 29.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

8.03 0.10 +1.26%
Market cap
$5.1M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
4/9
Altman Z
−2.78
Beneish M
−4.29
Dividend safety
n/a
Mar '26 Dec '25 Sep '25 Jun '25 Older periods
ROE
55.26% 69.76% 90.93% 92.42%

+8 more TTM periods

Piotroski F-Score
4 4 2 1
ROA
(32.70%) (35.86%) (36.64%) (37.61%)
ROIC
(12.61%) (16.99%) (23.73%) (25.55%)
Return on Tangible Assets
30.75% 37.37% (732.37%) (630.54%)
Average Days of Receivables
81.54 95.70 108.88 80.47
Free Cash Flow per Share
(6.78) (22.76) (18.00) (26.07)
Free Cash Flow
(4.28) (14.08) (11.18) (16.17)
Other line items

Show all line items

Columns are period end dates